Colorectal Cancer Clinical Trials

Showing 1-10 of 10 items
  • Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
  • The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes: 1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or 2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.
  • Diagnoses: Gastrointestinal Malignancies, Colorectal Cancer
  • Status: Recruiting
  • PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
  • The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.
  • Diagnoses: Colorectal Cancer, Gastrointestinal Malignancies
  • Status: Recruiting
  • Study of Vitamin D in Untreated Metastatic Colorectal Cancer
  • The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colorectal cancer. In this research study, the investigators are comparing standard and higher dose Vitamin D treatment when given in combination with standard treatment for metastatic colorectal cancer. Standard treatment includes the chemotherapy combination of 5-FU, Leucovorin and Oxaliplatin (FOLFOX) with bevacizumab.
  • Diagnoses: Gastrointestinal Malignancies, Colorectal Cancer
  • Status: Recruiting
  • PET/CT-Assessment of Liver Tumor Ablation
  • In this research study, the investigators are evaluating whether ammonia PET scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or freezing procedures (ablations) than other scans currently available to radiologists, such as CT scans and MRI scans. The currently available scan (usually a CT scan with contrast dye) is not always effective in showing how completely the tumor has been destroyed. The ammonia PET scan is a different way of looking at how much tumor has been destroyed. This study will compare the standard scan (CT scan) with the ammonia PET scan.
  • Diagnoses: Gastrointestinal Malignancies, Colorectal Cancer
  • Status: Recruiting
  • BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer
  • This is an open-label, three-part Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of trametinib (GSK1120212) and dabrafenib (GSK2118436) when administered in combination with the anti-EGFR antibody panitumumab in subjects with BRAF-mutation V600E or V600K positive colorectal cancer (CRC). Part 1 of the study will consist of dose-escalation cohorts Part 2 of the study will consist of expansion cohorts to investigate safety and clinical activity, and Part 3 of the study will be a randomized Phase II study comparing both the dabrafenib/panitumumab and dabrafenib/trametinib/panitumumab combinations to a chemotherapy comparator with respect to safety and clinical activity.
  • Diagnoses: Gastrointestinal Malignancies, Colorectal Cancer
  • Status: Recruiting
Showing 1-10 of 10 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms